Business Wire

Trove's Acquisition of reverse.supply Extends Resale Leadership to Europe

14.4.2025 14:00:00 CEST | Business Wire | Press release

Share

Following North American market leadership and its acquisition of Recurate, Trove extends global platform rollout with expanded European branded resale network

Trove, the leader in branded resale and customer trade-in, is advancing its European and global expansion by acquiring reverse.supply, a German-based leader in the European branded resale market. This acquisition marks a major milestone in Trove’s international platform rollout, making branded resale even more accessible, scalable, and operationally seamless for brands across 30 countries.

By combining Trove's established technology platform with reverse.supply's deep European expertise, Trove now offers the most comprehensive and scalable set of technology components for brands seeking to implement circular solutions in North America, Europe, and the UK. Core solutions include omnichannel trade-in, returns processing, peer-to-peer commerce, customer-facing resale solutions, marketplace integrations, and repair services. The deal follows international advancements that have laid the groundwork for this move, including Trove’s development of a global 3PL network, new capabilities in the UK, Europe and Canada, and a growing list of UK and EU brand partners.

"The acquisition comes at a strategic time as changing European legislation around producer responsibility and right-to-repair creates urgency for brands to establish effective resale, repair, and recycling programs,” said Terry Boyle, CEO of Trove. “By establishing our European headquarters in Berlin with a team that's been operating in resale for nearly five years, we're positioned to serve European and global brands seamlessly across regions and provide them with the full capabilities they need to launch and scale successful resale programs."

Trove's growing global client list now includes reverse.supply's impressive roster of European partners, including Bergzeit, Decathlon, ARMEDANGELS, Hessnatur, and 10Days. reverse.supply clients will gain access to Trove's full suite of technologies.

“We’re proud to be part of this important milestone. The acquisition enhances our ability to deliver greater strategic value to European brands and retailers,“ said Max Große Lutermann, co-founder of reverse.supply. “With our merged expertise and Trove’s technology, we can now offer a scalable, profitable circular solution that’s even more tailored to the specific needs of each brand or retailer.”

Janis Künkler, co-founder, added: “The timing of this transaction is pivotal, as brands and retailers in Europe are facing new legislation and actively seeking profitable, future-proof revenue streams. By bringing Trove’s proven technology to Europe, we’re positioned to help brands navigate these changes and build successful resale programs. This deal underscores both the relevance of resale and the strength of the European fashion market.”

The entire reverse.supply team will be joining Trove. The European headquarters will be located in Berlin and will be led by reverse.supply co-founders Janis Künkler and Max Große Lutermann.

This deal follows Trove's strategic acquisition of Recurate in August 2024, which significantly expanded Trove's offerings in peer-to-peer resale, Shopify integrations, and operational networks.

About Trove

Trove is at the forefront of the branded resale and trade-in industry, providing brands with a robust platform to efficiently launch, manage, and scale their resale programs. Trove is trusted by industry leaders such as Canada Goose, Carhartt, Michael Kors, Patagonia, On, Arc’teryx, Brooks and Steve Madden.

Trove’s platform features advanced tools, including in-store and digital trade-ins, returns processing, non-new inventory management, resale site building and management, Shopify integration, repair and recycling capabilities, and peer-to-peer technology. These features empower brands in North America, UK, and Europe to connect with new customers across all demographics, optimize resale strategies with comprehensive analytics, and maintain seamless operations across multiple channels.

As a Certified B Corporation, Trove is more than just a technology provider; it is a catalyst for sustainability in retail, driving the industry toward a future where commerce and environmental responsibility go hand in hand. To learn more, visit Trove.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250410321095/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye